The real risk isn't in running robust tests; it’s in wasting money or cutting high-performing channels based on misleading ...
When it comes to trials of any drug, size matters, potentially giving the World Health Organization's (WHO) gloomy verdict on Gilead Sciences' COVID-19 treatment remdesivir an edge over the company's ...
These 10-year results confirm that hypofractionated radiotherapy (68 Gy in 25 fractions) is non-inferior to conventionally fractionated radiotherapy (76 Gy in 38 fractions) for high-risk prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback